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The genus Mycobacterium includes several pathogens that cause severe dis-
ease in humans, like Mycobacterium tuberculosis (M. tb), the infectious
agent causing tuberculosis. Genetic tools to engineer mycobacterial gen-
omes, in a targeted or random fashion, have provided opportunities to
investigate M. tb infection and pathogenesis. Furthermore, they have
allowed the identification and validation of potential targets for the diagno-
sis, prevention, and treatment of tuberculosis. This review describes the
various methods that are available for the generation of mutants in
Mycobacterium species, focusing specifically on tools for altering slow-
growing mycobacteria from the M. tb complex. Among others, it incorpo-
rates the recent new molecular biological technologies (e.g. ORBIT) to
rapidly and/or genome-wide comprehensively obtain targeted mutants in
mycobacteria. As such, this review can be used as a guide to select the
appropriate genetic tools to generate mycobacterial mutants of interest,
which can be used as tools to aid understanding of M. tb infection or to
help developing TB intervention strategies.
The genus Mycobacterium includes several pathogens
that cause severe disease in humans. Tuberculosis
(TB), caused by Mycobacterium tuberculosis (M. tb), is
the world’s leading infectious killer, before HIV and
malaria, killing around 1.6 million people each year
[1]. Furthermore, the emergence of drug-resistant
strains constitutes a serious health threat and requires
innovative initiatives to stop the TB epidemic.
Genetic analysis of mycobacteria is essential to initi-
ate the understanding of M. tb infection. Furthermore,
it can aid developing TB intervention strategies, for
example by validating drug targets or engineering
improved live-attenuated vaccines. Many bacterial
genes and pathways that are vital for the intracellular
growth and survival of M. tb are known and several
of such bacterial virulence mechanisms have been sug-
gested as attractive drug targets [2,3]. Also in the field
of vaccine research, switching off important
immunomodulatory or virulence genes has shown
great promise to develop strains with an increased pro-
tective effect against M. tb [4–7]. Nevertheless, the lar-
gest part of the ~ 4000 genes in the mycobacterial
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genome remains unexplored. The functional validation
of the bacterial components presumed to be involved
in M. tb–host interactions, and the validation of candi-
date genes in M. tb or Mycobacterium bovis Bacillus
Calmette Guerin (BCG) for improved vaccine develop-
ment requires the generation of mutants.
Genetic engineering in mycobacteria is challenging
due the impenetrable nature of the mycobacterial cell
wall, the slow growth of the bacteria, and the
pathogenicity of some species. Furthermore, the high
frequency of illegitimate recombination [8] and the
availability of few antibiotic selection markers [9,10]
complicates the generation of genetically engineered
strains.
Over the past decades, a variety of genetic engineer-
ing approaches has been developed and the mycobac-
terial genetic toolbox has expanded dramatically. This
review aims to provide a guide for the generation of
mutants in Mycobacterium species. It focuses specifi-
cally on tools for altering slow-growing mycobacteria
from the M. tb complex.
Targeted mutagenesis
One-step and two-step allelic exchange using
vectors
The first systems that enabled mutagenesis of slow-
growing mycobacteria were based on one-step allelic
exchange (AE) (Fig. 1A) [11,12]. Therefore, mycobac-
teria are electroporated with suicide vectors (or linear
dsDNA) containing flanking sequences of a locus of
interest and an antibiotic resistance gene, whereafter a
double cross-over between the homologous regions on
the genome and the allelic exchange substrate (AES)
leads to the formation of a marked mutant. Later on,
direct repeats of recombination sites (e.g. FRT, loxP,
res, or dif sites) were incorporated to allow subsequent
site-specific recombination-mediated marker gene
removal (Table 1) [13–19].
Important improvements were made by applying a
two-step AE procedure to create unmarked mutants
(Fig. 1B) [20–22]. Different AES were designed con-
taining a.o. multiple resistance markers (KanR,
HygR), the lacZ gene and the negative selection mar-
ker SacB. In a first step, a single cross-over between a
genomic locus of interest and its region of homology
on the suicide vector integrates the entire construct
into the mycobacterial genome. These single cross-over
transformants are specifically selected for by a combi-
nation of one or multiple resistance markers and
optionally the visual LacZ screening tool, which turns
the cells blue when grown in the presence of X-Gal.
Since the marker genes are outside the region of
homology, double cross-over transformants or antibi-
otic-resistant false positives would remain white. In a
second step, the genome is forced to undergo a second
cross-over event to delete the negative selection marker
SacB by plating on medium containing sucrose. This
second cross-over can either occur between the regions
involved during the first cross-over, regenerating the
WT locus, or between up or downstream regions of
homology, generating an unmarked knockout (KO)
mutant. Since SacB shows a high rate of spontaneous
inactivation [23,24], a second screening mechanism
(blue/white screening or antibiotic sensitivity) is
advised. Barkan et al. [25] showed that the
Escherichia coli galactokinase gene (galK) can be used
as a counterselectable marker in mycobacteria, allow-
ing the introduction of both counterselection genes
(sacB and galK) on the delivery vectors for a tight
counterselection (up to 100%). Recently, Arnold et al.
[26] implemented this dual counterselection in their
optimized suicide vectors (the pKO series), that are
part of a uniform cloning platform (based on fragment
exchange using the type IIS restriction enzyme SapI)
to facilitate mycobacterial genetics (also includes vec-
tors for gene complementation, conditional knock-
downs and protein production).
These methods (or variations thereof) are still used
today to create AE mutants in both fast- and slow-
growing species, as they are easy to implement.
Although successful in many (but certainly not all)
cases, the above described methods remain cumbersome
and take on average 4–12 months to create a single KO
mutant. This is mainly due to the low efficiency of elec-
troporation to introduce foreign DNA into the
mycobacterial cells and the low rate of homologous
recombination (HR). Transformation efficiencies are
typically in the range of 103 to 105 transformants per
microgram of DNA for slow-growing Mycobacterium
species such as M. bovis BCG and M. tb [9]. Since typi-
cal recombination frequencies are in the range of 104
to 106 for single cross-overs and at least an order of
magnitude lower for double cross-over events, it is clear
that we are on the limit for reliably obtaining AE
mutants using this approach. Improvements were made
to overcome these limitations for example, by optimiz-
ing electroporation protocols [9,27,28] and by using
UV-irradiated or alkali-treated donor DNA to stimu-
late HR [20,29]. In 2017, a novel approach has been
published to transform mycobacteria, namely shock-
wave-assisted bacterial transformation [30], that uses a
number of consecutive shockwaves to introduce DNA
in mycobacteria. However, the maximum amount of
colony-forming units that could be attained was 105
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Fig. 1. One-step (A) or two-step (B) allelic exchange (AE) strategies using vector systems and specialized transduction (C). (A) One-step AE
involves a double cross-over between homology regions in the genome and the allelic exchange substrate (AES) on the delivery vector,
leading to the formation of a marked mutant, that can be unmarked by site-specific recombination. (B) In two-step AE, the first cross-over
will integrate the delivery vector in the genome. By applying negative selection, a second cross-over is forced, that will restore the WT
locus or generate an unmarked mutant. (C) Specialized transduction. First, the AES plasmid carrying homology regions to the gene of
interest (RH and LH) needs to be generated. Type II RE Van91I, recognizing a palindromic repeat that is interrupted by 5 bp of unspecified
sequence (CCANNNN^NTGG), can be used to construct the AES plasmid by means of a directional 4-fragment ligation step. This AES
plasmid and the shuttle phasmid (e.g. phAE159) are digested with PacI and ligated to form concatemers, which are packaged in vitro in k
particles (using the k cos site) for the transduction of Escherichia coli to isolate shuttle phasmids containing the gene-specific AES plasmid.
These are then electroporated to Mycobacterium smegmatis to generate the specialized transducing phage at permissive temperature
(30 °C). The generated phages can then be used to infect a Mycobacterium strain of interest at restrictive temperature (37 °C) to create
gene deletion mutants via double homologous recombination.
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transformants per lg DNA, which is comparable to the
optimized electroporation protocols.
In summary, the introduction of DNA in mycobac-
teria is one of the limiting factors to reliably obtain
AE mutants. This has been solved by the use of
phages; the exploration of the mycobacteriophage
diversity provided a method to efficiently introduce
foreign DNA in mycobacteria.
Specialized transduction
Mycobacteriophages are viral particles that are able to
naturally infect one or more Mycobacterium species
and have naturally evolved to very efficiently introduce
their phage DNA into the mycobacterial cell. With
appropriate adjustment of the multiplicity of infection,
almost every cell in the culture is transduced (~ 100%
transformation efficiency) [31–33]. Jacobs et al. [34]
pioneered their use as efficient gene transfer systems in
mycobacteria and coined the name ‘shuttle phasmid’.
An E. coli–Mycobacterium shuttle phasmid consists of
a conventional E. coli replicating plasmid inserted into
a nonessential region of the mycobacteriophage DNA,
allowing for the transfer of DNA across both genera.
Bardarov et al. [31] developed several temperature-sen-
sitive phasmid variants that are able to replicate and
form plaques at permissive temperature (30 °C), but
are unable to do so at restrictive temperature (37 °C).
The transformation efficiencies that can be reached
using mycobacteriophage delivery far exceed those using
electroporation. Therefore, transduction as a method to
introduce recombinant DNA into the mycobacterial cell
is perfectly suited to replace or knock out genes by HR.
This approach was first described by Bardarov et al. [35]
and has been termed specialized transduction. The
complete method consists out of several steps (Fig. 1C).
First, the plasmid expressing the AES needs to be con-
structed. The AES contains the regions of homology to
the gene of interest and a hygromycin resistance marker
flanked by resolvase recognition sites. The AES plasmid
also contains a PacI restriction site, a k cos site, and an
origin of replication for E. coli (OriE). Secondly, the
plasmid moiety of the temperature-sensitive shuttle phas-
mid is replaced by the gene-specific AES plasmid. There-
fore, both vectors (shuttle phasmid and AES plasmid)
are digested with PacI and ligated together with the for-
mation of concatemers (long DNA molecules containing
different copies of the two vectors). These concatemers
are in vitro packaged in phage k particles via the k cos
site on the AES plasmid and transduced into E. coli. The
circular cosmid DNA from hygromycin-resistant trans-
formants can then be isolated and electroporated to
Mycobacterium smegmatis. The cells are incubated at the
permissive temperature (30 °C) to allow phage replica-
tion, so that infectious phage particles can be isolated.
These phage particles can then be used to transduce any
Mycobacterium strain of interest at the restrictive temper-
ature (37 °C), inhibiting phage replication. Instead, the
cells can undergo a double cross-over to replace the
endogenous gene with a hygromycin-disrupted mutant
allele (like for the one-step AE strategy). After validation
of the mutation in the hygromycin-resistant transfor-
mants, the selection marker(s) can be removed by
transiently expressing the resolvase gene (tnpR).
Numerous genes have been knocked out using this
method in many Mycobacterium species, including
M. bovis BCG substrains [36–38], virulent M. tb
[39,40], and M. avium [41,42]. In 2014, an update of
this method was published [43], to improve upon sev-
eral rate-limiting steps of specialized transduction.
First, the authors shortened the multistep process of
engineering AES for HR to a one-step cloning proce-
dure by means of a type IIP restriction enzyme,
Van91I (or DraIII, BstAPI, or AlwNI) (Fig. 1C).
Therefore, the homology regions are both flanked by
Van91I sites. The vector can then be constructed by
means of a directional 4-fragment ligation (two
Van91I digested vector fragments and two Van91I-di-
gested PCR amplicons containing the homology
regions). If the sequence within the PCR amplicon
contains a Van91I recognition site, the restriction
enzyme BstAPI, AlwNI, or DraIII is used instead. Sec-
ondly, they reported on an improved shuttle phasmid
(phAE159) with an increased cloning capacity
(~ 10 kb for PhAE159 vs ~ 4.5 kb for PhAE87),
allowing the incorporation of more versatile genetic
constructs. Due to this increased cloning capacity, the
negative selection marker SacB could be incorporated
Table 1. Site-specific recombinase systems applied in
mycobacteria (slow- and fast growing) for marker gene removal
System Origin
Length
recognition
sites References
cd/res TnpR/res system
of the cd
transposon from
Escherichia
coli F episome
114 bp
res sites
[13,35,43,112]
FlpE/FRT Yeast Saccharomyces
cerevisiae 2-lm circle
34 bp
FRT sites
[14–16]
Cre/loxP Bacteriophage P1 34 bp
loxP sites
[14,17]
Xer/dif Endogenous Xer
recombinases
(XerC, XerD)
28 bp
dif sites
[18,19]
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in the AES, simplifying the subsequent removal of the
res-flanked cassette by counterselection on sucrose
medium. Lastly, they generated a conditionally repli-
cating resolvase-expressing phage (PhAE280) to
rapidly remove the res-(sacB-hygR)-res cassette from
the genome, obviating the curing step of the resolvase-
expressing plasmids. Using the improved method, the
authors have already generated over 100 confirmed
deletion mutants in M. tb H37Rv in diverse functional
gene classes.
Double- and single stranded recombineering
Although specialized transduction increases the effi-
ciency of mycobacterial transformation significantly
compared to traditional electroporation, the phage
construction step remains laborious and has to be
repeated for every gene KO. Furthermore, double
cross-overs by the endogenous HR machinery are still
rare events and in slow-growing strains such as M. bo-
vis BCG and M. tb, illegitimate recombination occurs
at a considerable incidence [8], further confounding
AE experiments.
The efficiency of recombination-based genetic engi-
neering, also known as recombineering, can be pro-
moted 10- to 100-fold by use of phage-encoded
recombineering systems. First used in yeast [44], the
method in its most popular form was first imple-
mented in E. coli [45,46]. In 2007, van Kessel and Hat-
full implemented the gp60 and gp61 proteins of
mycobacteriophage Che9c to stimulate recombineering
in mycobacteria [47]. The authors optimized an induci-
ble (acetamidase promoter-based) expression system
for the gp60 and/or gp61. Cells expressing gp60 and
gp61 were induced with acetamide and transformed
with linear dsDNA containing an AES. In M. tb, they
observed an increase in HR that was at least an order
of magnitude higher compared to control strains not
expressing the recombineering proteins. An update of
the system used a temperature-sensitive recombineering
plasmid containing a SacB counterselection marker for
straightforward curing of the plasmid afterward, a
visual screening tool (GFP) to allow easy discrimina-
tion of the recombined transformants and site-specific
recombination sites to allow subsequent removal of
introduced resistance markers [17].
Next to dsDNA recombineering, introduction of
ssDNA oligo’s in cells expressing the ssDNA-binding
protein gp61 was shown to allow the precise introduc-
tion of point mutations into the mycobacterial genome
[48]. Although the authors mainly focused on directly
selectable target genes, they also showed the system’s
potential for gene mutations without a selectable
phenotype [48]. Herefore, the ssDNA oligo was elec-
troporated in excess together with a vector carrying a
co-selectable marker. The basic idea is to eliminate all
nontransformed cells and enrich for the transformed
ones that are likely to have incorporated the mutated
oligo into the genome as well. In M. smegmatis, 5–
10% of resistant transformants also had the desired
mutation, while this was an order of magnitude lower
in M. tb (0.5–1%).
However, now more than 10 years later, few labora-
tories appear to have picked up ssDNA recombineer-
ing as a genetic engineering tool. It is likely that its
use to introduce nonselectable mutations in slow-grow-
ing mycobacterial species is cumbersome, since the
recombineering efficiency in these types of mycobacte-
ria is 5- to 10-fold reduced compared to M. smegmatis
and further depends on the sequence context of the
oligo and target locus within a species [48]. Altogether,
this necessitates the screening of 100–1000 single clones
to identify a single clone with the mutation of interest,
without an a priori knowledge that the mutation is
present. This laborious screening appears to be a
major bottleneck in the ssDNA recombineering
approach.
Enhanced specialized transduction using
recombineering
Tufariello et al. [49] further optimized mycobacterial
genetic engineering by combining the excellent trans-
formation efficiencies of transducing phages with an
increased recombination by the Che9C recombineering
proteins, leading to a 10- to 100-fold increase in the
number of transformants. Deletion of mycobacterial
RecD (involved in the repair of double stranded breaks
(DSB) [50]) further increased the AE efficiency in
M. tb several fold, both in the presence and absence of
the recombineering system [49]. Altogether, specialized
transduction in a recombineering and DrecD back-
ground improved gene replacement efficiencies 100- to
150-fold compared to the WT M. tb strain [49]. While
recombineering is generally applicable in any
Mycobacterium species, the DrecD phenotype requires
the generation of a recD disruption strain in advance.
Nevertheless, these substantial improvements gave rise
to a consortium of laboratories, seeking to create a
genome-wide set of KO phages to disrupt all nonessen-
tial mycobacterial genes in various M. tb backgrounds
[43,49,51] or any other close relative such as M. bovis
BCG. Once the rate-limiting step of phage construc-
tion is completed, the semi-high throughput engineer-
ing of any slow-growing Mycobacterium species
appears within reach.
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ORBIT, oligonucleotide-mediated recombineering
followed by Bxb1 integrase targeting
The Hatfull lab did vast amounts of work to charac-
terize different phage systems, including the Che9
RecET recombineering system [48,52] and the Bxb1
phage integration system [53–60]. Their huge efforts
enabled the Sassetti lab to develop a new system for
targeted mutagenesis of mycobacteria, namely ORBIT
(Oligonucleotide-mediated Recombineering followed
by Bxb1 Integrase Targeting), which was recently
published [61]. The system combines two efficient
phage recombination systems to create a versatile
method for chromosomal engineering of mycobacte-
ria, with the possibility of generating both deletions
and insertions or fusions using essentially the same
method.
Two phage proteins are involved in the ORBIT sys-
tem (Fig. 2A–D). First, the Che9c RecT annealase
incorporates a synthetic targeting oligonucleotide
(ssDNA) (attP site flanked by 45–70 bp homology
arms) into the chromosome via HR, resulting in the
introduction of an attP site at a precise location in the
chromosome. Subsequently, the Bxb1 integrase inte-
grates a ‘payload plasmid’ in the genome via attP-attB
site-specific recombination, creating an attL and attR
site flanking the integrated payload plasmid. The pay-
load plasmid contains a selectable marker to select for
the correctly engineered strains. The targeting oligonu-
cleotide and payload plasmid are co-transformed into
a RecT and Int-expressing strain allowing the selection
of drug-resistant homologous recombinants in a single
step [61].
Depending on the nature of the targeting oligonu-
cleotide and payload plasmid, one can create KOs,
insertions (e.g. fusion of C-terminal tags) or replace-
ments (e.g. promoter replacement). For KOs, the
oligonucleotide is designed to replace the target gene
by the attP site (Fig. 2C). For C-terminal tags, the
oligonucleotide is designed to insert the attP site
before the stop codon of the gene, after which a pay-
load plasmid is used to introduce the tag (Fig. 2D).
Murphy et al. generated a set of payload plasmids to
create C-terminal targeted fusions, facilitating fluores-
cence analysis and affinity purifications. To construct
promoter replacement, the oligonucleotide is designed
to replace the endogenous promoter with the attP site
and the payload plasmid will subsequently introduce
the alternative promoter. Using ORBIT, the authors
were able to construct insertions and deletions in over
100 genes in M. smegmatis and M. tb. They docu-
mented that typically 20–200 clones are obtained per
transformation (~ 6 mL starting culture electroporated
with 1 lg targeting oligonucleotide and 200 ng
payload), whereafter only 2–4 candidates need to be
analyzed by PCR to identify at least one correct clone
[61].
The advantages of this method for generating dele-
tion mutants are obvious. Instead of generating
dsDNA substrates (or specialized transduction phages)
for the generation of a mutant via AE, you just need
to design one chemically synthesized oligonucleotide,
which makes the method well suited for the construc-
tion of libraries of mutants. Moreover, the generated
mutation is selectable, in contrast a mutation obtained
by ssDNA recombineering. Furthermore, the system
not only allows the creation of gene deletions, but also
supports the generation of C-terminal fusions, pro-
moter replacements, and so on. Additionally, each
generated mutant can be tagged by including a unique
DNA barcode sequence in the targeting oligonu-
cleotide. The diversity of modifications that can be
made with different payload plasmids offers new possi-
bilities for functional screening of mutant libraries gen-
erated with ORBIT [61].
A disadvantage of this method, compared to special-
ized transduction, is that an electroporation step is
needed to introduce the targeting oligonucleotides and
payload plasmid, limiting the overall efficiency of the
method. Additional drawbacks of the system are the
remaining vector, producing the recombination func-
tions, and the remaining selection marker in the
mutants. The negative selection marker SacB was
already added to the vector, generating pKM461, to
permit straightforward curing of this plasmid (Fig. 2A)
[61]. Moreover, the remaining selection marker can be
removed by introducing the Bxb1 integrase and gp47
protein (recombination directionality factor) [57], that
will promote site-specific recombination between the
created attL and attR sites, restoring the attP site and
thereby removing the selection marker (Fig. 2E). This
process was already shown to work for M. smegmatis
gene deletion mutants [61], not yet for slow-growing
mycobacteria. If needed, one could introduce the nega-
tive selection marker GalK on the payload plasmid to
make the removal of the selection marker more
straightforward. However, iterative construction of
strains containing multiple mutations using ORBIT
could be challenging due to the remaining attP site in
the genome. For this it would be recommended to first
introduce all the desired different mutations and then,
in a final step, all mutations could be unmarked at the
same time. Especially here, the introduction of a
counterselectable marker on the payload would be
advisable.
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Gene editing with CRISPR-CAS?
CRISPR or Clustered Regularly Interspaced Short
Palindromic Repeat sequences are a distinct class of
repetitive DNA sequences across the prokaryotic
domain, that are commonly associated with CRISPR-
associated (Cas) proteins [62,63]. These CRISPR-Cas
systems provide some primitive form of cell immunity
against phage infections, by degrading invading DNA
sequences [64]. The CRISPR-Cas9 system of Strepto-
coccus pyogenes has been successfully implemented for
genome editing [65] in numerous organisms across the
eukaryotic kingdom, ranging from yeast [66] to human
cell lines [67–69] and complete higher eukaryotic model
organisms [70–73]. In eukaryotic cells, DSBs intro-
duced by Cas9 can efficiently be repaired by NHEJ
(nonhomologous end joining) to create indel mutations
(or by homology-directed repair using repair templates)
[74]. However, most bacterial species lack NHEJ capac-
ity, therefore the reports on the use of CRISPR-Cas
for targeted genome editing in bacterial organisms
came later on [75–78].
In the field of CRISPR-Cas, it became generally
known that the use of the CRISPR-Cas9 system to
create mutants in bacteria (including mycobacteria
[79]) is restricted due to the toxicity of SpCas9 (S. pyo-
genes Cas9). In CRISPR interference (CRISPRi), a
catalytically dead Cas9 (dCas9) is used and no DSBs
are generated, which allows the use of CRISPR-dCas9
systems to achieve gene silencing in mycobacteria [80–
82]. Luckily, the natural diversity of Cas effector pro-
teins opened opportunities for the field.
The first successful application of CRISPR-Cas gene
editing in M. smegmatis used a mycobacterium codon-
optimized FnCpf1 (Francissella novicida CRISPR-asso-
ciated endonuclease in Prevotella and Francisella 1) in
combination with oligonucleotide recombineering
(CRISPR-Cas12a-assisted recombineering) to create
markerless and scarless mutations [83]. Mycobacteria
are first transformed with FnCpf1 (tetracyclin-inducible
promoter) and the Che9c gp60 and gp61 recombineer-
ing proteins. Thereafter, a temperature-sensitive plas-
mid expressing a crispr RNA (crRNA) targeting the
gene of interest and disruption oligonucleotides
(ssDNA or markerless dsDNA) are transformed into
the cells. The formed crRNA-Cas12a complexes will
bind and cut the gene of interest. The created DSB is
repaired by recombineering, resulting in point muta-
tions, deletions or insertions, depending on the admin-
istered oligonucleotides. The efficiency of introducing a
site-directed mutation by CRISPR-Cas12a-assisted
recombineering ranged from 60% to 80% (using
ssDNA oligonucleotides) [83], while the insertion/dele-
tion efficiency depended on the length of these inser-
tions and deletions (~ 30–60% efficiency for 1 kb
deletions using markerless dsDNA) [83]. In M. smeg-
matis, CRISPR-Cas12a-assisted recombineering thus
gives a clear advantage over markerless recombineering
without Cpf1 (only 5–10% efficiency) [47].
Sun et al. [79] thereafter published the successful
application of the CRISPR-FnCpf1-assisted NHEJ sys-
tem in M. smegmatis, without the addition of recombi-
neering proteins or a homologous DNA template. For
gene editing, cells are simply transformed with one plas-
mid coexpressing FnCpf1 (hsp60 promoter) and a
crRNA targeting a specific gene. In this system, the
generated DSBs are repaired by NHEJ (adding addi-
tional nucleotides or resulting in deletions) [79], in con-
trast to the CRISPR-Cas12a-assisted recombineering
system of Yan et al. [83], where no NHEJ was detected.
The CRISPR-FnCpf1-assisted NHEJ system in
Fig. 2. ORBIT. (A, B) Plasmids and oligonucleotide constructs for ORBIT. (A) Construct pKM461 expresses the recombination functions,
including the Che9c phage RecT annealase and the Bxb1 phage integrase (Int), both driven from the Ptet promoter. It additionally contains
the negative selection marker SacB for straightforward curing of the plasmid after the mutant has been created. This replicating plasmid
needs to be transformed to the strain to prepare it for ORBIT (B) Targeting oligonucleotide and nonreplicating payload plasmid. The targeting
oligonucleotide (ssDNA) consists of the Bxb1 attP site (48 bases) flanked by 45–70 bases of homology at each side to the target gene (LH
and RH), while the payload plasmid provides the Bxb1 attB site. To generate gene fusions, the attB site is flanked by the fusion gene/tag
designed to be in frame with the target gene. (C, D) ORBIT-promoted gene deletion (C) or EGFP-fusion to the target gene (D).
Mycobacterial cells expressing both RecT annealase and Bxb1 integrase are coelectroporated with the targeting oligonucleotide and the
payload plasmid. The ORBIT process is initiated at the replication fork. RecT annealase promotes annealing of the targeting oligonucleotide
to the lagging strand template of the replication fork, integrating the attP site at a precise location in the chromosome. Subsequently, Bxb1
will promote site-specific recombination between this attP site and the attB site on the payload plasmid, resulting in the site-specific
integration of the payload plasmid in the genome. For gene deletions (C) the oligonucleotide is designed so that the attP site replaces the
target gene. For EGFP fusion (D) the oligonucleotide is designed so that the attP site is inserted before the stop codon, allowing in frame
fusion of the EGFP tag to the target gene. In both cases, one can select for the successful recombinants by applying hygromycin selection.
(E) Markerless gene deletions can be created by introducing the excision plasmid (pKM512) in the cells. This excision plasmid expresses the
Bxb1 integrase and gp47 protein (a recombination directionality factor, RDF), that will promote site-specific recombination of the attL and
attR sites, restoring the attP site and thereby deleting the selection markers. Figure adapted from Murphy et al. [61].
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M. smegmatis has an editing efficiency as high as 70%
and takes 9 days for one round of genome editing (in-
stead of 16 days with HR [17,47]).
Further studies are required to investigate the appli-
cations of catalytically active Cas variants for genome
editing in slow-growing mycobacteria. A low survival
rate upon the formation of the DSB could limit the
feasible implementation of the CRISPR-FnCpf1-as-
sisted NHEJ system in slow-growing mycobacteria.
Possibly, regulation of Cas9 expression could help
improve the outcome of NHEJ-mediated DSB repair.
However, a high amount of CRISPR escapers could
impede the straightforward identification of positive
clones [79].
Random mutagenesis using
transposons
Analyzing transposon mutant behavior in bulk
In the previous sections, we extensively discussed vari-
ous site-directed gene replacement methods. Although
the combination of specialized transduction and
recombineering significantly improved AE efficiencies
[49], the phasmid cloning steps remain time-consum-
ing, putting an impediment on the real high-through-
put construction of genome-wide mycobacterial
deletion mutants. The ORBIT method already circum-
vents this time-consuming step, but creating a genome-
wide mutant library in a gene-by-gene approach is still
laborious. To this end, bulk mutant creation
approaches are better suited, the most popular one
being transposon mutagenesis. In its most common
implementation, the Himar1 Mariner transposon (ran-
domly inserting at TA dinucleotides) is transduced in
the mycobacteria, allowing the generation of high-den-
sity transposon insertion libraries [31,84].
Using transposon mutagenesis, numerous genetic
screens were conducted to elucidate genotype–pheno-
type relationships in different mycobacterial species.
Phenotypic screens with individual mutants are limited
by the assay’s low throughput and the laborious steps
to identify the site of insertion. Therefore, different
semi-high throughput methods were designed (e.g.
genomic footprinting [85–87], signature-tagged mutage-
nesis [32,88,89]) to assay large mutant pools. Sassetti
et al. [90] were the first to develop a genome-wide
approach using micro-array-based analysis, namely
Transposon Site Hybridization or TRASH. However, it
was the implementation of second-generation sequenc-
ing technologies that transformed the field. It allowed
to monitor individual transposon mutants within a
complex mixture by sequencing the transposon
junctions that characterize each mutant, using a high-
throughput, next-generation parallel sequencing
approach [91]. After sequencing and data processing,
the various conditions are probed for transposon dis-
rupted genes that are depleted (or enriched), implicating
their essential (or disadvantageous) roles in a particular
condition. Since the initial publications [92–95], trans-
poson sequencing (Tn-seq) is now the method of choice
to unravel genotype–phenotype relationships in a wide
range of bacteria [96]. In mycobacteria, Tn-seq has
especially been used for probing the essentiality status
of genes [97–100]. Furthermore, it has been used for
synthetic genetic array analyses [101–103], assigning a
function to several hypothetical mycobacterial genes by
uncovering interactions with known genes or pathways.
From tracking individual transposon mutants to
characterizing complete transposon libraries
using CP-CSeq
Findings resulting from the analysis of transposon
mutant behavior in bulk (e.g. via transposon sequenc-
ing) need to be validated and this often requires regen-
eration of individual mutants via conventional
methods. Isolating individual mutants from an
archived library was typically done by PCR on pooled
subsets, scaling down until a single mutant was con-
firmed [4,104]. Only few laboratories have put thor-
ough effort in compiling larger sets of gene disruption
mutants, available for the Mycobacterium research
community. McAdam et al. [105] generated a resource
of 1329 unique Tn5370 insertion mutants in the M. tb
H37Rv strain, disrupting in total 351 ORFs. To obtain
this, 2280 individual mutants were subjected to a geno-
mic DNA preparation step, followed by a few rounds
of PCR and sequencing to determine the transposon
flanking genomic regions that determine the site of
insertion. A similar approach was taken in the M. tb
CDC1551 clinical isolate [106], obtaining mutants in
878 genes with an initially comparable library size
(1425 insertions). These early resources of M. tb
mutants created a basis for further research into
Mycobacterium biology [107].
Characterization of mycobacterial transposon
libraries through clone-by-clone sequencing of the trans-
poson flanking regions is possible, but is obviously very
laborious [105,106]. Some methods were developed to
characterize sequence-tagged biological entities such as
mutants or cloned DNA [93,108,109]. All these
approaches depend on the use of combinatorial pooling
strategies in which pools are assigned barcodes. The
identity of each specimen in the library is thus encoded
within the pooling pattern. Deconvolution of this
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pattern allows to position the original specimen in the
library. Using such combinatorial pooling, the number
of pools can be kept much smaller than the number of
specimens, allowing to drastically reduce the down-
stream workload. In general, these combinatorial meth-
ods are dependent on robotic equipment, that is not
readily accessible for many scientists. Furthermore, the
combinatorial pooling strategies are complex and
require complex bioinformatics.
Our laboratory developed a method that is highly
intuitive and uses the most common operational mode
of liquid/clone handling robots, namely CP-CSeq or
Cartesian-Pooling Coordinate Sequencing (Fig. 3)
[110]. The method combines a 3D pooling strategy
along the Cartesian coordinates with multiplex trans-
poson sequencing to form a characterized ordered
transposon library. These sample transfers (described
in Fig. 3A) are so intuitive that they can even be per-
formed using manual or electronic 96 channel pipets,
making the method accessible to any laboratory,
including those without robots.
We demonstrated this approach in the M. bovis BCG
Pasteur 1721 (streptomycin-resistant) strain, creating a
transposon library of 96 9 96-well plates (containing
6383 traceable mutants) targeting up to 64% of the
nonessentialM. tb orthologues [110]. Transposon muta-
genesis combined with CP-CSeq is thus an excellent tool
to rapidly build libraries of genome-wide transposon
insertion mutants in an isogenic background. CP-CSeq
should enable any laboratory to characterize existing
ordered transposon libraries, enhancing the utility of
such mutant resources. Mutants of interest identified in
Tn-seq experiments can then be easily extracted from
the characterized library for validation of the Tn-seq
findings or thorough investigation of the transposon
mutant in question.
In fact, the method’s concept is applicable to any
entity for which sequence-tagged identification is possi-
ble, so any insertional mutant type; incl. specialized
transduction mutants. We envision that the combina-
tion of enhanced specialized transduction in bulk
(transducing a library of specialized transducing
phages each targeting a single gene to ΔrecD mycobac-
terial strain expressing pJV53) and CP-CSeq can be
used to rapidly generate an archived genome-wide
mutant library in different mycobacterial strains. This
would circumvent the need to separately transduce the
strain of interest with the different phages. Performing
ORBIT in bulk, by transforming array-synthesized
oligonucleotide libraries and one payload plasmid,
seems unachievable (at the moment) as it relies on
electroporation to transform the targeting oligonu-
cleotides and payload plasmid, which limits the overall
efficiency of the method and circumvents its feasible
upscaling.
In 2017, Barczak et al. [111] published on the sys-
tematic, multiparametric analysis of M. tb intracellular
infection to identify novel functional relationships
between genes that play a role in infection. They cre-
ated a transposon library of ~ 26 000 individual trans-
poson mutants (~ 270 9 96-well plates), which they
characterized by performing colony PCR (using a two-
step process with one primer inside the transposon and
one random primer for each PCR step) followed by
Sanger sequencing to identify each transposon inser-
tion site. The authors do not report on the implemen-
tation of combinatorial pooling to reduce the
processing steps, neither do they mention the use of a
robotic system to perform these vast amounts of col-
ony PCRs and Sanger sequencing (26 000 in total).
Nonetheless, this library is currently the largest
resource of archived transposon mutants in any strain
of the M. tb complex, probably targeting up to 90%
of all nonessential M. tb genes [110]. Yet, neither com-
plete list of all transposon insertions nor resource
statistics was reported. From this parental transposon
library of ~ 26 000 transposon mutants, 2660 trans-
poson mutants were selected to create an arrayed,
nonredundant M. tb transposon mutant library which
were screened in macrophages using high-content
imaging, to systematically identify M. tb genes
required for growth in infected host cells [111].
Creating clean knockouts from transposon
mutants
Although transposon insertion mutants are extremely
valuable assets for fundamental mycobacterial
research, they also have a few drawbacks. First of all,
the mutants are generated by pseudo-random inser-
tions, often leading to a loss-of-function, but to a
sometimes unpredictable extent. This is inherently dif-
ferent from a classical KO mutant where part of the
DNA sequence is removed in a predetermined way.
Furthermore, the foreign DNA on the transposon
increases the risk of polar effects, as these sequences
can alter gene expression profiles of nearby up- and
downstream genes. This necessitates extensive molecu-
lar and phenotypic characterization of each mutant
before a certain function can be attributed to the gene
in which the transposon insertion has occurred. In
addition, the presence of the antibiotic selection mar-
ker hinders further engineering efforts (only one other
effective antibiotic resistance marker being available,
namely hygromycin) and it excludes the use of such
mutants as vaccines (clean mutants are required for
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Fig. 3. Cartesian Pooling-Coordinate Sequencing (CP-CSeq) concept for simultaneously determining the position of the transposon insertions
in the genome and the coordinates of the transposon mutants in the library. (A) Layout and Cartesian Pooling of a library of 96 9 96-well
plates of transposon insertion mutants. Each entity’s position in the library is characterized by three Cartesian coordinates (X, Y, and Z). To
create the first masterplate, the X–Y Pool Plate, a small culture volume of one specific well position (for example, A1) in all of the 96-well
plates is transferred to and thus pooled in the same specific well (for example, A1) of the masterplate, thus keeping the respective
positions within each primary plate (X and Y-coordinates). Subsequently, a second masterplate, the Z pool plate, is prepared by pooling all of
the 96 wells of a primary plate in one single well of the masterplate (Z-coordinate) and doing this for each primary plate. As such all
mutants of the first plate will be present in the first well and all mutants of the last plate in the last well of the Z pool plate. Next, each row
and each column of both masterplates are pooled in column (n = 12) and row (n = 8) pools, giving a total of 40 samples that represent a
library of 96 9 96 clones. Each mutant in the library is present in 4 of the 40 pools, as illustrated for a mutant in well E4 plate 96, keeping
the positional information of each mutant. (B) Coordinate-Seq sequencing library preparation links a pool-specific barcode to the sequence
tag that identifies each transposon mutant in each pool. (C) Coordinate-Sequencing data processing for transposon insertion mutants.
Figure adapted from Vandewalle et al. [110].
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clinical trials). Finally, reversion of a transposon
mutant back to WT is theoretically possible in the
exceedingly unlikely case that the bacterium would be
transformed by DNA encoding for the entirely heterol-
ogous transposase. Nevertheless, transposon insertion
mutants are highly valuable for fundamental mycobac-
terial research, but are currently difficult to develop
for further clinical development (e.g. vaccine trials) as
live-attenuated strains.
We developed a (semi-) high-throughput methodol-
ogy to create genome-wide clean deletion mutants, by
implementing molecular recombination and excision
tools in the transposon mutagenesis toolbox (unpub-
lished data). In this way, genome-wide transposon
mutant resources can be rapidly generated with an
option, to afterward, efficiently remove (most of) the
foreign transposon DNA. For this, a derivative of the
original Himar1 transposon was constructed (Fig. 4A,
B). We implemented two systems to create unmarked
mutants: FRT-sites for FlpE/FRT-mediated site-specific
recombination and I-SceI sites for I-SceI meganuclease
(ISceIM)-based transposon removal (Fig. 4C). The first
approach inherently leaves an FRT scar, whereas the
last one has the potential of creating clean, markerless
mutants. Different genetic carriers were investigated to
bring in these unmarking proteins. For fast-growing
mycobacteria like M. smegmatis, replicable vectors
proved to be the best option, whereas temperature-sen-
sitive phages (similar to PhAE280) or tetracyclin-in-
ducible replicable vectors (optionally containing the
GalK counterselectable marker for subsequent plasmid
curing) were the best option for unmarking slow-grow-
ing mycobacteria (M. bovis BCG Danish) (unpublished
data).
The I-SceI system provides a new way to remove
marker genes from mycobacteria and can now be
implemented in other mutagenesis methods (like two-
step AE, dsDNA recombineering, specialized transduc-
tion and ORBIT). The system mostly results in small
indels of different sizes, but in a small percent of cases
Fig. 4. Creating clean knockouts from transposon mutants using an optimized Himar1 transposon. (A) Visual representation of the original
Himar1 transposon (~ 2 kb); it consists of a kanamycin resistance marker (KanR) and an origin of replication for Escherichia coli (OriE)
flanked by two inverted repeats (IR). (B) Optimized Himar1 transposon (~ 4 kb); it consists of a KanR, an OriE, and a SacB negative
selection marker (to select for unmarked transposon mutants) flanked by two FRT sites, two I-SceI sites, and two IR. (C) Illustration of the
construction of a transposon mutant (marked) using the optimized transposon and subsequent unmarking strategies by bringing in FlpE
recombinase or I-SceI meganuclease (ISceIM) into the cells and selecting the unmarked mutants. FlpE/FRT-mediated recombination
inherently leaves an FRT scar in the unmarked transposon mutant, whereas ISceIM-based transposon removal has the potential of creating
clean mutants in which all heterologous DNA is removed. Figure adapted from Borgers et al. (unpublished data).
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bigger deletions are formed (percentages differ depend-
ing on the mycobacterial strain (unpublished data). So,
screening is required to identify clones of interest hav-
ing a small indel or a larger deletion. However, unlike
site-specific recombination systems, no intact I-SceI
sites remain in the genome (both I-SceI sites are
destroyed), excluding the risk for unwanted genomic
rearrangements due to remaining recognition sites.
By combining the use of CP-CSeq and the optimized
transposon in the M. bovis BCG Danish 1331 (WHO
reference, NIBSC 07/270) vaccine strain, we created a
very large resource of BCG transposon mutants, from
which clean KOs can be generated. The created
resource in BCG Danish (two sets of 96 9 96-well
plates containing 15 000 traceable transposon mutants)
approaches genome saturation, as it targets 83% of all
nonessential genes (excluding duplicated genes) (un-
published data). Unmarking of these transposon
mutants only requires a straightforward introduction
of ISceIM (via electroporation or transduction) and a
colony PCR screen with custom primers on the genes
of interest. As such, this research contributes to the
global goal of creating genome-wide KO mutants in
multiple strains of the M. tb complex.
For the creation of genome-wide mutant resources
in different mycobacterial backgrounds, we envision
the use of transposon mutagenesis in combination with
CP-CSeq to target the bulk of the nonessential genes
(~ 80%), with a cost of less than 3 € per characterized
and library-localized mutant. The low cost of the
method makes it worthwhile to repeat the method in
different strains, if there is a good biomedical incentive
for it. The remaining genes (~ 20%), that are hard to
target via transposon mutagenesis (short genes and/or
contain few TA’s), could then be targeted by ORBIT
[61] or specialized transduction [43,49].
Conclusion
Mycobacterial tools to make mutants have come a long
way. The initial attempts to make mutants in these
unruly bacteria were inefficient and cumbersome. With
the refinement of specialized transduction [43,49], the
development of ORBIT [61] and the new tools for trans-
poson mutagenesis (including CP-CSeq [110] and the
optimized transposon (unpublished data)), the creation
of mutants in slow-growing mycobacteria has become
feasible. The characteristics of the available methods are
summarized in Table 2. Furthermore, several research
groups have done (or are doing) the effort to create
large mutant resources and make them publicly avail-
able to the scientific community in order to nurture
mycobacterial research all over the world [43,49,51,105–
107,115]. Such resources are soon to be truly genome-
wide, which will be a milestone for research on human-
ity’s most deadly pathogen. Finally, the implementation
of CRISPR-Cas gene editing in M. smegmatis provides
hope that we can implement CRISPR-Cas gene editing
in slow-growing mycobacteria in a feasible manner,
although this still needs to be tested. Moreover, the long
duration until this is reported suggests that unforeseen
problems are encountered.
The powerful repertoire of mycobacterial genetic
tools that is now available will speed up the elucida-
tion of mycobacterial pathogenesis and drug resistance
pathways. Moreover, it facilitates the development of
Table 2. Characteristics of the different methods available for mutagenesis of slow-growing mycobacteria. References to key publications
for the methods are included
Method
Strain
background Introduction of
Resulting
mutants are Extra requirements
Targeted mutagenesis
One-step allelic exchange [11,12] WT AES via electroporation Marked –
Two-step allelic exchange [20–22] WT AES via electroporation Unmarked –
Specialized transduction [35,43] WT AES via transduction Marked –
dsDNA recombineering [17,47] gp60, gp61 AES via electroporation Marked –
ssDNA recombineering [48] gp61 Targeting oligo via
electroporation
Unmarked Extensive screening
Enhanced specialized transduction [49] gp60, gp61,
optional ΔrecD
AES via transduction Marked –
ORBIT [61] gp60, gp61 Targeting oligo and
payload via electroporation
Marked –
Random mutagenesis
Transposon mutagenesis WT Transposon construct via
transduction [31,84]
(or electroporation [113,114])
Marked Characterization of ordered
libraries for example
via CP-CSeq [110]
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new anti-TB drugs and vaccines in the battle against
TB.
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